Patients with chronic kidney disease are often taken off RAS inhibitors after declines in kidney function, but the risks may ...
Black Diamond Therapeutics bets on brain-penetrant EGFR drug silevertinib, targeting C797S resistance and CNS metastases as key edge in crowded lung cancer market.
Abbisko Therapeutics (HKEX: 02256) announced that the company presented six latest preclinical and translational research ...
FDA NDA acceptance positions zipalertinib for post-systemic-therapy EGFR ex20ins NSCLC, with a February 27, 2027 PDUFA target ...
NDA submission based on the Phase 2b REZILIENT1 clinical trial, which demonstrated clinically meaningful and durable ...
BDTX rides on silevertinib, with 2026 durability data set to test early NSCLC efficacy and CNS signals, making upcoming readouts a decisive swing factor.
MedPage Today on MSN
Moderate Diet Change Tied to Renal Benefit in CKD
Findings suggest protein restriction doesn't have to be extreme ...
Acceptance of the New Drug Application is based on findings from a phase 2b portion of the open-label REZILIENT1 clinical trial.
Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with ...
Researchers uncover how mutant lung cells reshape surrounding tissue through signaling loops with fibroblasts and immune ...
A phase 1/2 trial shows strong early efficacy for daraxonrasib plus chemotherapy as first-line treatment for patients with metastatic pancreatic cancer — but toxicity is a concern.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results